Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

Jones, Peter H.; Cusi, Kenneth; Davidson, Michael; Kelly, Maureen; Setze, Carolyn M.; Thakker, Kamlesh M.; Sleep, Darryl J.; Stolzenbach, James C.

doi:10.2165/10061630-000000000-00000

Cited by 36 publications

(25 citation statements)

References 32 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, a pooled subgroup analysis of three randomized, controlled, double-blind, 12-week trials that included 586 patients with mixed dyslipidemia and T2DM showed that the fenofibric acid/statin combination treatment was associated with a significantly greater improvement of lipid profile compared with either monotherapy [157]. Indeed, it was shown that the combination of fenofibric acid with low-or moderate-dose statin, led to a 5-fold higher percentage of patients achieving the combined optimal levels of LDL-C, non-HDL-C, apoB, TG and HDL-C [157].…”

Section: Effects Of Statin and Fibrate Combination On Metabolic Parammentioning

confidence: 99%

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

et al. 2013

View full text Add to dashboard Cite

■ AbstractType 2 diabetes mellitus (T2DM) is associated with the development and progression of cardiovascular disease (CVD). Statins have an established efficacy in the management of dyslipidemia primarily by decreasing the levels of lowdensity lipoprotein cholesterol and thus decreasing CVD risk. They also have a favorable safety profile. Despite the statin-mediated benefit of CVD risk reduction a residual CVD risk remains, especially in T2DM patients with high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) values. Fibrates decrease TG levels, increase HDL-C concentrations, and improve many other atherosclerosis-related variables. Fibrate/statin co-administration improves the overall lipoprotein profile in patients with mixed dyslipidemia and may reduce the residual CVD risk during statin therapy. However, limited data exists regarding the effects of statin/fibrate combination on CVD outcomes in patients with T2DM. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study the statin/fibrate combination did not significantly reduce the rate of CVD events compared with simvastatin/placebo in patients with T2DM. However, it did show a possible benefit in a pre-specified analysis in the subgroup of patients with high TG and low HDL-C levels. Furthermore, in the ACCORD study the simvastatin/fenofibrate combination significantly reduced the rate of progression of retinopathy compared with statin/placebo administration in patients with T2DM. The present review presents the available data regarding the effects of statin/fibrate combination in patients with T2DM and atherogenic mixed dyslipidemia.

show abstract

Section: Effects Of Statin and Fibrate Combination On Metabolic Parammentioning

confidence: 99%

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Several recent studies have demonstrated the efficacy and safety of fenofibric acid and statin therapy in patients with mixed dyslipidemia in reducing triglycerides and raising HDL-C compared with statin monotherapy. 37,38 NOVEL HDL THERAPIES This complex process involved in RCT provides multiple targets to modulate HDL metabolism with novel therapies. RCT involves the efflux of free cholesterol (FC) in the macrophage to discoidal pre-b1 HDL.…”

Section: Statin-niacin Combination Therapymentioning

confidence: 99%

Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction

Davidson

2011

Cardiology Clinics

Self Cite

View full text Add to dashboard Cite

“…Three statin medications have been tested: rosuvastatin, simvastatin, and atorvastatin. These trials found an added increase in HDL over that achieved with statin alone: 16 [21]. Enhanced reduction of triglycerides was also seen: 43.9% decrease (299.9 to 158.4 mg/dL [3.39 to 1.79 mmol/L]) with the statin/fenofibrate combination.…”

Section: Fibric Acid Derivatives Plus Statin Therapymentioning

confidence: 98%

Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes

Bonds

2011

Curr Cardiovasc Risk Rep

View full text Add to dashboard Cite

Diabetes remains a significant risk factor for cardiovascular disease. One potential cause of this excess risk is the higher proportion of dyslipidemia among patient with type 2 diabetes. Although statin therapy has been shown to improve lipid profiles of patients with diabetes and reduce their risk of cardiovascular disease, there remains a residual risk. Further optimization of the lipid profile of these patients through reduction in triglycerides and improvement in high-density lipoprotein levels has the potential to further reduce the cardiovascular risk. This article reviews several pharmacologic treatments aimed at achieving this optimization and provides an overview of recent clinical trials testing these strategies.

show abstract

Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

Cited by 36 publications

References 32 publications

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction

Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes

Contact Info

Product

Resources

About